TY  - JOUR
TI  - Modification with Conventional Surfactants to Improve a Lipid-Based Ionic-Liquid-Associated Transcutaneous Anticancer Vaccine
ID  - scholars18666
KW  - antigen; immunological adjuvant; lipid; surfactant; vaccine
KW  -  animal; C57BL mouse; cutaneous drug administration; drug delivery system; mouse
KW  -  Adjuvants
KW  -  Immunologic; Administration
KW  -  Cutaneous; Animals; Antigens; Drug Delivery Systems; Lipids; Mice; Mice
KW  -  Inbred C57BL; Surface-Active Agents; Vaccines
N2  - Transcutaneous vaccination is one of the successful, affordable, and patient-friendly advanced immunization approaches because of the presence of multiple immune-responsive cell types in the skin. However, in the absence of a preferable facilitator, the skinâ??s outer layer is a strong impediment to delivering biologically active foreign particles. Lipid-based biocompatible ionic-liquid-mediated nanodrug carriers represent an expedient and distinct strategy to permit transdermal drug delivery; with acceptable surfactants, the performance of drug formulations might be further enhanced. For this purpose, we formulated a lipid-based nanovaccine using a conventional (cationic/anionic/nonionic) surfactant loaded with an antigenic protein and immunomodulator in its core to promote drug delivery by penetrating the skin and boosting drug delivery and immunogenic cell activity. In a follow-up investigation, a freezeâ??dry emulsification process was used to prepare the nanovaccine, and its transdermal delivery, pharmacokinetic parameters, and ability to activate autoimmune cells in the tumor microenvironment were studied in a tumor-budding C57BL/6N mouse model. These analyses were performed using ELISA, nuclei and HE staining, flow cytometry, and other biological techniques. The immunomodulator-containing nanovaccine significantly (p < 0.001) increased transdermal drug delivery and anticancer immune responses (IgG, IgG1, IgG2, CD8+, CD207+, and CD103+ expression) without causing cellular or biological toxicity. Using a nanovaccination approach, it is possible to create a more targeted and efficient delivery system for cancer antigens, thereby stimulating a stronger immune response compared with conventional aqueous formulations. This might lead to more effective therapeutic and preventative outcomes for patients with cancer. © 2023 by the authors.
N1  - cited By 3
IS  - 7
AV  - none
VL  - 28
A1  - Uddin, S.
A1  - Islam, M.R.
A1  - Moshikur, R.M.
A1  - Wakabayashi, R.
A1  - Moniruzzaman, M.
A1  - Goto, M.
JF  - Molecules
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152322299&doi=10.3390%2fmolecules28072969&partnerID=40&md5=3fe66001e06bbce0fdbceff21aa43182
Y1  - 2023///
ER  -